Rashid Lui 雷諾信

At our first ever co-organized event by the Hong Kong Society of Digestive Oncology with the Hong Kong Society for Coloproctology, we had the distinct pleasure of inviting Prof Dion Morton, OBE as our keynote speaker sharing his insights on neoadjuvant therapy in colon cancer. Also had the opportunity to share on neoadjuvant immunotherapy in #CRC #GIoncology

Delighted to have the opportunity to present about fecal microbiota transplantation #FMT alongside @wingyanjoyce @loeymak and @edmundwumd at the #HAConvention2026 on recent advances in GI services

Prof Tony Mok from CUHK welcomes you to ESMO TAT Asia Congress 12-14 June 2026 in Hong Kong, registration ends on 13th May ! esmo.org/meeting-calend…

We've known how important the tumor microenvironment is for cancer progression and treatment, but we never had a non-invasive blood test to assess it. Today, as reported @nature, one has been discovered nature.com/articles/s4158…

🔟 Must-Read in GI Oncology | Apr 27–May 3 A week of momentum across early-phase innovation, translational science, and real-world evidence👇 🔬 Highlights: • COMPANION-002: PFS + ORR improvement in BTC • MONTBLANC: Phase II HCC fully enrolled • COLOSOTO: Fast enrollment (KRAS G12C mCRC) • mFOLFOXIRI → CRT: ORR 30.8%, pCR 20.5% (LARC) • CEA-directed T cell engager + 4-1BB: MSS CRC strategy • Nano-273: overcoming IO resistance (preclinical) • Anal cancer cohort: CRT outcomes • CME meta-analysis: survival benefit • FDA early access: pancreatic cancer • Risk models: earlier detection 💡 Takeaway: Progress is driven by early-phase + translational + real-world convergence. @VivekSubbiah @RashidLui @staclinds @DuxinSun @N_BenKhaled @JuliaMayerle @EnricoNDeToni @forghy @JMarescauxIrcad @ElieRassy @StefanMichiels @TPudlarz @david_tougeron 📎oncodaily.com/oncolibrary/10… #GIOncology #Oncology #CancerResearch #Immunotherapy #CRC #PancreaticCancer #HCC #BTC #ClinicalTrials #OncoDaily

✨ ICI in localized CRC (#ASCO26 ed book) 🔹 dMMR/MSI-H → unprecedented responses 🔹 Rectal MSI-H → watch & wait as organ-preserving 🔹 ctDNA: promising, not yet practice-changing 🔹 MSS CRC → major unmet need 🚀 Moving toward precision, response-adapted strategies 🔗 doi.org/10.1200/EDBK-2…

Happy to share our latest study from @CUHKMedicine led by Prof #BrigetteMa and #SimonNg on the promising role of neoadjuvant FOLFOXIRI followed by capecitabine-based chemoradiation in Chinese patients with high-risk #LARC ! 📌 ORR for mFOLFOXIRI 30.8% 📌 pCR 20.5% 📌 Manageable toxicities 📌 IGF2 expression was associated with a detrimental impact on disease-free survival academic.oup.com/oncolo/advance… #GIoncology #CRC

Barrett’s esophagus is detected in 3 to 14% of adults with symptoms of gastroesophageal reflux disease (GERD) who undergo an endoscopy examination. Barrett’s esophagus is characterized by the replacement of the squamous mucosa in the lower portion of the esophagus with a columnar epithelium. On endoscopy, the columnar-cell–lined segment appears as reddened mucosa originating from the gastroesophageal junction and is frequently associated with a hiatal hernia. Histopathological findings include a mosaic of intestinal and gastric cell types. Clinically, a diagnosis of Barrett’s esophagus is established when endoscopic findings reveal a columnar epithelium measuring at least 1 cm long in combination with confirmed goblet-cell lineages, a condition termed intestinal metaplasia ([X: seen in figure | IG: seen in figure; swipe left for video]). Endoscopists record the length of the segment of Barrett’s esophagus in centimeters because longer segments are associated with a greater chance of progression to cancer. On the basis of historical studies, 3 cm is used as a cutoff between short segments (<3 cm) and long segments (≥3 cm). Establishing whether a segment is short or long determines how often monitoring should take place owing to the altered pathophysiological features of long segments with intestinal-cell lineages coupled with greater molecular instability. Learn more in the Clinical Practice article “Barrett’s Esophagus” by Rebecca C. Fitzgerald, MD (@RFitzgerald_lab), from the University of Cambridge (@cambridge_uni): nej.md/48nNRxV

The @US_FDA has granted rapid expanded access to daraxonrasib for metastatic pancreatic cancer, based on the phase 3 RASolute 302 trial which showed a reduced risk of death by 60% compared with chemotherapy, with manageable toxicities #PDAC #GIoncology fda.gov/news-events/pr…

🔥New @myESMO mCRC guidelines! 👉Precision oncology at the core 👉Clear biomarker hierarchy 👉Locoregional strategies in limited disease 👉Patient characteristics & preferences central Read more: doi.org/10.1016/j.anno…

Finally out in @AGA_CGH! 📝 Our HK population-based observational study demonstrated a lower 2-year risk of complicated #UGIB in apixaban users compared to edoxaban (NNH 244) and rivaroxaban (NNH 427). 🚨 cghjournal.org/article/S1542-…

Honoured! The #WATERLANDtrial (Ringer vs Saline for fluid resuscitation in acute pancreatitis) has been selected as one of the top 6 abstracts at the @DDWMeeting @isabial_iis @Lguilabert1 @EurPancClub @aegastro @my_ueg

【Heartfelt Congratulations to the MBChB Class of 2026! 👏】 Around 260 recent graduates successfully passed their MBChB exams on 17 April. Dressed in new white coats embroidered with their names, they celebrated with the Faculty Dean, teachers, and alumni, sharing their joy and pride.

This is the second abstract I was waiting for the whole @AACR #AACR26 #Daraxonrasib +GemNabPablitaxel in #mKRAS #PDAC in #FirstLine (GI-102 Platform) Phase I/II trial 40 pts ORR 58% DCR 90% 84% free of progresion at 6 months Ongoing Phase III 303 (Dara vs GemNab+/-Dara)

Fatty pancreas disease affects ~1 in 2 patients with MASLD 🧬 Pooled prevalence: 54.3% across 21,438 patients ⚠️ More common outside Asia (75.1% vs 35.6%) 📈 Linked to older age, higher BMI, diabetes, HTN & metabolic syndrome 🔗 onlinelibrary.wiley.com/doi/10.1111/jg…

Check out the April issue of the Journal of #Gastroenterology and #Hepatology 📗 #TealJournal ✳️ Fatty Pancreas in MASLD ✳️ Probiotics for IBS: Updated Meta-Analysis ✳️ EUS for Pancreatic NETs: Review ✳️ Pediatric Crohn's Disease Management And more 🔗 onlinelibrary.wiley.com/toc/14401746/2…

Delighted to share our latest review on H pylori naive gastric cancer penned together with our @dukenus @mysgh GI and @cuhksurgery surgery friends karger.com/dig/article/do… #GIoncology @CUHKMedicine @yubintan89 @LouisHSLau @shannonchan_hk @pwychiu

@drkeithsiau @chat_pedsgi Or detachable snare

What would you if you found this polyp on colonoscopy?

Does a combination of genetics and clinical risk factors help identify those at higher risk of liver cancer? In this prospective study from Singapore 🇸🇬 the answer appears to be yes @apage__official @HungNLuu1 @ELC_APAGE @AASLDtweets @NUSMedicine onlinelibrary.wiley.com/doi/10.1111/ap…

Asia is now the global epicenter of colorectal cancer 🌏 FIT-based screening in 🇯🇵 🇰🇷 🇹🇼 saves lives ➡️ reducing CRC mortality and proving cost-effective. The future? 🎯 Risk-based screening 📉 Earlier detection 🔬 Smarter, personalized strategies 🔗 onlinelibrary.wiley.com/doi/10.1111/jg…